Sanofi Pasteur announced last week that it has completed the third phase of its clinical study for a vaccine candidate in Latin America aimed at eliminating dengue fever.

Approximately 21,000 children ages nine to 16 from dengue-endemic areas including Brazil, Colombia, Mexico, Honduras and Puerto Rico were given three injections of the dengue vaccine.

According to the study, the vaccine—effective against all four strains of dengue—reduced the instance of the disease in children and adolescents by approximately 61 percent. Hospitalization as a result of the disease was reduced by 80 percent.